#None #Copenhagen #digital health #Dawn Health #Pharma Solutions

Dawn Health Secures €11.5 Million for Expansion

Dawn Health, a prominent player in digital health solutions, has announced the closing of a funding round amounting to €11.5 million. The investment comes from existing stakeholders including Chr. Augustinus Fabrikker, the Danish Export and Investment Fund (EIFO), and Trifork. This financial boost is set to strengthen Dawn Health's strategy of delivering its comprehensive product suite to pharmaceutical companies worldwide through a Software as a Service (SaaS) model, while also investing in new offerings within its portfolio.

Since its inception in 2021, Dawn Health has dedicated itself to creating a world-class platform tailored to meet the specific needs of the pharmaceutical industry. The Dawn Platform and Product Suite have already gained traction among major industry leaders, including Merck and Novartis. This platform addresses several critical areas such as oncology, multiple sclerosis, and rare pediatric diseases, like growth disorders, enabling patients to manage their treatment effectively, report symptoms, and maintain direct communication with their healthcare teams.

The capabilities of the Dawn Platform empower pharmaceutical companies, patients, and healthcare professionals to enhance patient outcomes and care quality, leveraging advanced technologies in artificial intelligence, data analytics, clinical integrations, personalization, and connected health. By refining data collection and analysis processes, these capabilities benefit both patients and pharmaceutical companies, establishing the Dawn Platform as a vital component for therapeutic companions, disease management programs, and real-world evidence (RWE) solutions that are shaping the future of digital healthcare.

CEO Alexander Mandix Hansen stated, "Our ambition is to become the global leader in digital health, driving next-generation pharmaceutical products and ultimately improving the lives of patients around the globe. This funding allows us to bring our proven platform to more markets and deepen our impact."

This new phase in Dawn Health's journey reinforces its position as a reliable partner for pharmaceutical companies, offering scalable, regulatory-compliant digital health products that evolve alongside the demands of modern medicine. President Lars Marcher noted, "Since our significant investment in December 2021, Dawn Health has significantly increased its revenue and expanded its footprint in the global pharmaceutical sector. With over 100 employees and unique solutions, along with a robust regulatory infrastructure, we are well-positioned to accelerate our growth even further."

About Dawn Health

Dawn Health is a global leader in digital health, specializing in the development of Software as a Medical Device (SaMD), Digital Therapeutics (DTx), and connected health solutions. By expediting the market launch of digital solutions, Dawn Health's product range fosters innovation to transform the lives of individuals with chronic illnesses. Through close collaboration with the life sciences sector, Dawn Health creates digital health products that revolutionize patient care with an empathetic and human-centered approach.

To learn more about Dawn Health, visit www.dawnhealth.com.